BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mirandola S, Campagnolo D, Bortoletto G, Franceschini L, Marcolongo M, Alberti A. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hepat. 2011;18:e212-e216. [PMID: 21692935 DOI: 10.1111/j.1365-2893.2011.01435.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 de Almeida Ribeiro CR, Martinelli KG, da Motta de Mello V, Spitz N, Araújo ORC, Lewis-ximenez LL, Araujo NM, de Paula VS. Association of Pre-S/S and Polymerase Mutations with Acute and Chronic Hepatitis B Virus Infections in Patients from Rio de Janeiro, Brazil. Viruses 2022;14:1375. [DOI: 10.3390/v14071375] [Reference Citation Analysis]
2 Qian F, Zou W, Jin F, Li D, Shen Y. Prevalence of Potential Resistance Related Variants Among Chinese Chronic Hepatitis B Patients Not Receiving Nucleos(T)ide Analogues. Infect Drug Resist 2020;13:2407-16. [PMID: 32765014 DOI: 10.2147/IDR.S249476] [Reference Citation Analysis]
3 Qiu J, Chen W, Zhang Y, Zhou Q, Chen J, Yang L, Gao J, Gu X, Tang D. Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors. Eur J Med Chem 2019;176:41-9. [PMID: 31091479 DOI: 10.1016/j.ejmech.2019.05.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Di Lello FA, Ridruejo E, Martínez AP, Pérez PS, Campos RH, Flichman DM. Molecular epidemiology of hepatitis B virus mutants associated with vaccine escape, drug resistance and diagnosis failure. J Viral Hepat 2019;26:552-60. [PMID: 30576055 DOI: 10.1111/jvh.13052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
5 Rezanezhadi M, Mohebbi A, Askari FS, Hosseini SD, Tabarraei A. Hepatitis B virus reverse transcriptase polymorphisms between treated and treatment-naïve chronically infected patients. Virusdisease 2019;30:219-26. [PMID: 31179360 DOI: 10.1007/s13337-018-00510-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Geng C, Yang T, Huang X, Yang J, Ma Y, Li T, Zhang X, Chen J. Anti-hepatitis B virus effects of the traditional Chinese herb Artemisia capillaris and its active enynes. Journal of Ethnopharmacology 2018;224:283-9. [DOI: 10.1016/j.jep.2018.06.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
7 Choi YM, Lee SY, Kim BJ. Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression. World J Gastroenterol 2018; 24(16): 1708-1724 [PMID: 29713126 DOI: 10.3748/wjg.v24.i16.1708] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
8 Asan A, Sayan M, Akhan S, Tekin Koruk S, Aygen B, Sirmatel F, Eraksoy H, Tuna N, Köse S, Kaya A, Eren Tulek N, Aktug Demir N, Mistik R, Ormen B, Korkmaz F, Yildirmak T, Ural O, Aydin M, Turgut H, Gunal O, Demirturk N. Molecular Characterization of Drug Resistance in Hepatitis B Viruses Isolated from Patients with Chronical Infection in Turkey. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.12472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Rajoriya N, Combet C, Zoulim F, Janssen HLA. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? J Hepatol. 2017;67:1281-1297. [PMID: 28736138 DOI: 10.1016/j.jhep.2017.07.011] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 13.4] [Reference Citation Analysis]
10 Li B, Guo QL, Tian Y, Liu SJ, Wang Q, Chen L, Dong JX. New Anti-HBV C-Boivinopyranosyl Flavones from Alternanthera philoxeroides. Molecules 2016;21:336. [PMID: 26985888 DOI: 10.3390/molecules21030336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
11 Xu J, Gu W, Li C, Li X, Xing G, Li Y, Song Y, Zheng W. Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha. J Nat Med 2016;70:584-91. [PMID: 26968537 DOI: 10.1007/s11418-016-0980-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
12 Gonen C, Gunduz F, Doganay L, Enc FY, Yegin EG, Ahishali E, Erdem E, Sokmen M, Tuncer I, Ozdogan O. High treatment modification rates with lamivudine therapy in HBV-infected patients with low baseline viremia and early virological response: A multicenter study. J Dig Dis 2015;16:286-92. [PMID: 25708813 DOI: 10.1111/1751-2980.12237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Zhao Y, Wu J, Sun L, Liu G, Li B, Zheng Y, Li X, Tao J. Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China. Braz J Infect Dis. 2016;20:173-178. [PMID: 26876337 DOI: 10.1016/j.bjid.2015.12.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
14 Bivigou-Mboumba B, François-Souquière S, Deleplancque L, Sica J, Mouinga-Ondémé A, Amougou-Atsama M, Chaix ML, Njouom R, Rouet F. Broad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon. PLoS One 2016;11:e0143869. [PMID: 26764909 DOI: 10.1371/journal.pone.0143869] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
15 Geng C, Huang X, Chen X, Ma Y, Rong G, Zhao Y, Zhang X, Chen J. Three new anti-HBV active constituents from the traditional Chinese herb of Yin-Chen (Artemisia scoparia). Journal of Ethnopharmacology 2015;176:109-17. [DOI: 10.1016/j.jep.2015.10.032] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
16 Zhou B, Dong H, He Y, Sun J, Jin W, Xie Q, Fan R, Wang M, Li R, Chen Y, Xie S, Shen Y, Huang X, Wang S, Lu F, Jia J, Zhuang H, Locarnini S, Zhao GP, Jin L, Hou J. Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. Sci Rep 2015;5:17123. [PMID: 26599443 DOI: 10.1038/srep17123] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
17 Fan J, Zhang Y, Xiong H, Wang Y, Guo X. Nucleotide analogue-resistant mutations in hepatitis B viral genomes found in hepatitis B patients. J Gen Virol. 2015;96:663-670. [PMID: 25481755 DOI: 10.1099/jgv.0.000010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
18 Cho YK, Cui XJ, Jeong SU, Song BC. Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Antiviral Res 2014;112:8-17. [PMID: 25303802 DOI: 10.1016/j.antiviral.2014.09.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
19 Su CW, Wu CY, Hung HH, Wu CH, Sheen IJ, Wu JC. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy. J Gastroenterol Hepatol. 2013;28:1849-1858. [PMID: 23730852 DOI: 10.1111/jgh.12283] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
20 Hønge BL, Jespersen S, Medina C, Té Dda S, da Silva ZJ, Lewin S, Østergaard L, Erikstrup C, Wejse C, Laursen AL, Krarup H; Bissau HIV cohort study group. Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study. PLoS One 2014;9:e99971. [PMID: 24915064 DOI: 10.1371/journal.pone.0099971] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
21 Zhang Y, Zhang Y, Kang Y, Wang J, Liu H, Zhu H, Qin Y, Mao R, Lin X, Lu M, Zhang J. Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus. Journal of Virological Methods 2014;201:51-6. [DOI: 10.1016/j.jviromet.2014.02.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
22 Chen J, Yan L, Zhu FC, Liu JX, Li RC, Wang FZ, Li J, Zhuang H. Amino acid polymorphism in the reverse transcriptase region of hepatitis B virus and the relationship with nucleos(t)ide analogues treatment for preventing mother-to-infant transmission. J Med Virol. 2014;86:1288-1295. [PMID: 24777553 DOI: 10.1002/jmv.23948] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
23 Vutien P, Trinh HN, Garcia RT, Nguyen HA, Levitt BS, Nguyen K, da Silveira E, Daugherty T, Ahmed A, Garcia G. Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients. Clin Gastroenterol Hepatol. 2014;12:1363-1370. [PMID: 24342744 DOI: 10.1016/j.cgh.2013.11.036] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
24 Xu Z, Wu G, Li F, Bai J, Xing W, Zhang D, Zeng C. Positive selection signals of hepatitis B virus and their association with disease stages and viral genotypes. Infection, Genetics and Evolution 2013;19:176-87. [DOI: 10.1016/j.meegid.2013.07.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
25 Moehlen M, De Medina M, Hill M, Jeffers L, Schiff ER, Martin P. Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy. ISRN Hepatol 2013;2013:130384. [PMID: 27335823 DOI: 10.1155/2013/130384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
26 Coppola N, Tonziello G, Colombatto P, Pisaturo M, Messina V, Moriconi F, Alessio L, Sagnelli C, Cavallone D, Brunetto M, Sagnelli E. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. J Infect. 2013;67:322-328. [PMID: 23796869 DOI: 10.1016/j.jinf.2013.06.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
27 Alvarez Estévez M, Chueca-Porcuna N, Guillot-Suay V, Peña-Monje A, García-García F, García-García F. [Low prevalence of hepatitis B virus primary drug resistance in Southern Spain]. Enferm Infecc Microbiol Clin 2013;31:520-2. [PMID: 23602529 DOI: 10.1016/j.eimc.2013.02.014] [Reference Citation Analysis]
28 Kim DY, Chang HY, Lim SM, Kim SU, Park JY, Kim JK, Lee KS, Han KH, Chon CY, Ahn SH. Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B. Gut Liver 2013;7:329-34. [PMID: 23710315 DOI: 10.5009/gnl.2013.7.3.329] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
29 Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life. Int J Med Sci. 2013;10:427-433. [PMID: 23471472 DOI: 10.7150/ijms.5472] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
30 Morando F, Rosi S, Fasolato S, Cavallin M, Gola E, Gatta A, Angeli P. Severe acute hepatitis B in a treatment-naïve patient with antiviral drug resistant mutations in the polymerase gene. J Med Virol 2013;85:210-3. [DOI: 10.1002/jmv.23448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
31 Mirandola S, Sebastiani G, Rossi C, Velo E, Erne EM, Vario A, Tempesta D, Romualdi C, Campagnolo D, Alberti A. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy. Antiviral Res. 2012;96:422-429. [PMID: 23026293 DOI: 10.1016/j.antiviral.2012.09.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
32 Wang C, Fan R, Sun J, Hou J. Prevention and management of drug resistant hepatitis B virus infections: Facing antiviral drug resistance. Journal of Gastroenterology and Hepatology 2012;27:1432-40. [DOI: 10.1111/j.1440-1746.2012.07198.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lanini S, Garbuglia AR, Puro V, Solmone M, Martini L, Arcese W, Nanni Costa A, Borgia P, Piselli P, Capobionchi MR. Hospital cluster of HBV infection: molecular evidence of patient-to-patient transmission through lancing device. PLoS One. 2012;7:e33122. [PMID: 22412991 DOI: 10.1371/journal.pone.0033122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]